Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03023241

Enrollment

300

Registered

2017-01-18

Start date

2004-12-31

Completion date

2021-07-31

Last updated

2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Pain Syndrome, Interstitial Cystitis, Overactive Bladder

Keywords

BPS/IC, OAB

Brief summary

To identify new, simple and reliable biomarkers for bladder pain syndrome/interstitial cystitis (BPS/IC) for diagnosis of this disease.

Detailed description

Collection and analyses of bladder biopsies, bladder washings, blood and urine samples of patients with bladder pain syndrome/interstitial cystitis (BPS/IC), overactive bladder syndrome (OAB) and bladder-healthy controls. Analyses include ELISA, RT-qPCR, DNA sequencing, and immunohistochemistry techniques. Differences between patient groups are statistically evaluated.

Interventions

PROCEDUREbiopsy

cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patient with diagnosed BPS/IC, OAB or healthy controls * included healthy controls must have another pelvic surgery planned (e.g. hysterectomy) * being able to act and judge

Exclusion criteria

* unstable endocrinological situation * severe illness

Design outcomes

Primary

Measure	Time frame
Identification of new diagnostic markers for BPS/IC	2 days

Secondary

Measure	Time frame
Identification of molecular details that lead to BPS/IC (pathogenesis).	2 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026